Depression Clinical Trials in Cleveland, OH

24 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	<1 mi
Positive Processes and Transition to Health - Single-Session (PATH-SS)	N/A	Case Western Reserve University	<1 mi
Positive Processes and Transition to Health (PATH)	N/A	Case Western Reserve University	<1 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	<1 mi
Developing Resilience and Anxiety Management Through the Arts	N/A	Case Western Reserve University	<1 mi
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women	N/A	BTL Industries Ltd.	7 mi
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)	Phase 2	Seaport Therapeutics	10 mi
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	10 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)	Phase 3	Xenon Pharmaceuticals Inc.	10 mi
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder	Phase 2	Sirtsei Pharmaceuticals, Inc.	10 mi
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)	Phase 2	Autobahn Therapeutics, Inc.	10 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	11 mi
ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Alto Neuroscience	12 mi
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	12 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	12 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	17 mi
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	17 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	17 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	17 mi
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response	Phase 2	ACADIA Pharmaceuticals Inc.	46 mi
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	46 mi
Study to Assess the Safety and Effectiveness of NMRA-335140-501	Phase 3	Neumora Therapeutics, Inc.	46 mi
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)	Phase 2	atai Therapeutics, Inc.	46 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.